Abstract
Objective: We assessed the reproducibility of the acute test with single dose bisoprolol 1,25 mg (Test) on FEV1, FVC and acute bronchodilator response to salbutamol 400 mcg in patients with bronchial asthma (BA) or chronic obstructive pulmonary disease (COPD) and arterial hypertension (AH).
Methods: 15 patients (aged 58,9±7,0 years) with AH and COPD (n=5) or BA (n=10) underwent repeat Test 2 weeks after first Test employing the same technique. The FEV1 and FVC were assessed initially, after 30, 90, 150, 240min and after up to 30min salbutamol 400mcg. Measurements were compared between first (W0) and repeat spirometry (W2) using correlation coefficients and Bland-Altman plots.
Results: FEV1 initially was 72,9±24,3% at W0 and 73,1±25,6% at W2. In 30, 90, 150 and 240 min at W0 and at W2 FEV1 was 74,0±25,1% and 76,8±23,3%; 73,7±24,6% and 76,7±24,3%; 73,7±24,2% and 73,0±25,9%; 73,0±23,3% and 73,4±24,8% respectively. FVC initially was 82,2±19,5% at W0 and 79,8±22,5% at W2 and did not change significantly at W0 and W2. After administration of salbutamol increase of FEV1 up to 78,3±22,7% at W0 and 77,2±23,3% at W2 was registered. The bronchodilating effect of salbutamol on D%FEV1 was +9% (p<.01) at W0 and +7% (p=.01) at W2. The FVC also increased significantly up to 85,8±18,8% (p<.01) at W0 and 82,0±19,3% (p<.01) at W2. There was excellent correlation between W0 and W2: FEV1 (r=0.98, p<.001), FVC (r=0.98, p<.001), bronchodilating effect of salbutamol on D%FEV1 (r=0.52, p<.05). Mean differences between W0 and W2 were small and Bland-Altman plots showed no association between difference and value.
Conclusion: spirometry measurements of FEV1 and FVC in acute test with single dose bisoprolol 1,25 mg are highly reproducible over time.
- © 2014 ERS